Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD45RA- Depleted PBSC Grafts for GVHD Prevention in Non-Malignant Diseases
NCT07660783Phase 2Not yet recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2026
- Primary completion
- Sep 2031
- Countries
- 1
01
Overview
Phase 2, open-label trial in graft-versus-host disease (GVHD) (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Graft Versus Host Disease-free Survival at 1 year. Planned start Sep 2026; status: not yet recruiting.
02
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07660783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07660783.